Cargando…

Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure

Heart failure (HF) remains the leading cause of death, morbidity, and medical expenses worldwide. Treatments for HF with reduced ejection fraction have progressed in recent years; however, acute decompensated heart failure remains difficult to treat. The transient receptor potential (TRP) channel fa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Kun, Gui, Yang, Hou, Xu, Ye, Lifang, Wang, Lihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204593/ https://www.ncbi.nlm.nih.gov/pubmed/35722101 http://dx.doi.org/10.3389/fcvm.2022.904881

Ejemplares similares

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials
por: Chen, Yan, et al.
Publicado: (2022)

B-Type Natriuretic Peptide (BNP) Revisited—Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?
por: Nishikimi, Toshio, et al.
Publicado: (2022)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
por: Li, Kangbo, et al.
Publicado: (2023)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
por: Verbrugge, Frederik H., et al.
Publicado: (2020)

Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation
por: Zhu, Tianyu, et al.
Publicado: (2022)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
por: Cho, In-Jeong, et al.
Publicado: (2021)

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
por: Kashiwagi, Yusuke, et al.
Publicado: (2023)

Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study
por: Hsiao, Fu-Chih, et al.
Publicado: (2022)

Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism
por: Kashiwagi, Yusuke, et al.
Publicado: (2022)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
por: Choi, Hong-Mi, et al.
Publicado: (2020)

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure
por: Sun, Yuxi, et al.
Publicado: (2021)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II–Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension
por: AlSiraj, Yasir, et al.
Publicado: (2021)

The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022
por: Xu, Xia, et al.
Publicado: (2022)

Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study
por: Williams, Bryan, et al.
Publicado: (2014)

Is there a place for angiotensin receptor-neprilysin inhibitors in the treatment of heart failure patients after heart transplantation?
por: Gulin, Dario, et al.
Publicado: (2019)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
por: Taghavi, Sepideh, et al.
Publicado: (2020)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
por: Ryazanov, A.S., et al.
Publicado: (2023)

Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases
por: Nakagawa, Hitoshi, et al.
Publicado: (2022)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure
por: Pfau, Daniel, et al.
Publicado: (2019)

Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper
por: Ntalianis, Argyrios, et al.
Publicado: (2021)

Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure
por: Mukhopadhyay, Amrita, et al.
Publicado: (2022)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
por: Park, Su Yeong, et al.
Publicado: (2023)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

Role of Transient Receptor Potential Canonical Channels in Heart Physiology and Pathophysiology
por: Wen, Hairuo, et al.
Publicado: (2020)

Combined Angiotensin Receptor–Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure
por: Trivedi, Rishi K., et al.
Publicado: (2018)

Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction
por: Grant, Andrew D.M., et al.
Publicado: (2020)

Increased concentrations of bioactive adrenomedullin subsequently to angiotensin‐receptor/neprilysin‐inhibitor treatment in chronic systolic heart failure
por: Arfsten, Henrike, et al.
Publicado: (2020)

The Impact of Angiotensin Receptor–Neprilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-analysis
por: Mujadzic, Hata, et al.
Publicado: (2022)

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
por: Tsai, Ming-Lung, et al.
Publicado: (2023)

Real-world Practical Experience of Angiotensin Receptor-neprilysin Inhibitor in Older Japanese Patients with Chronic Heart Failure
por: Komatsu, Toshinori, et al.
Publicado: (2023)

Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists
por: Dalal, Jamshed, et al.
Publicado: (2023)

Long‐term impact of angiotensin receptor‐neprilysin inhibitor based on short‐term treatment response in heart failure
por: Park, Hyuk Kyoon, et al.
Publicado: (2023)

Angiotensin receptor-neprilysin inhibitor therapy and recurrence of atrial fibrillation after radiofrequency catheter ablation: A propensity-matched cohort study
por: Dong, Youzheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8j8gqs1gn7p4m52eaokfgsj6d4